Following FDA approval of Imaavy, we explore promising biotech candidates in development for myasthenia gravis.

New research reveals light sensitivity significantly impacts quality of life in myasthenia gravis patients, highlighting the ...

The primary endpoint of the trial is safety and tolerability, and key secondary endpoints include myasthenia gravis activities of daily living scale (MG-ADL) and quantitative myasthenia gravis (QMG) ...

The primary endpoint was the difference between nipocalimab and placebo in the 24-point Myasthenia Gravis Activities of Daily Living (MG-ADL) scale in the intention-to-treat population of 153 ...

The primary endpoint of the trial is safety and tolerability, and key secondary endpoints include Myasthenia Gravis Activities of Daily Living Scale (MG-ADL) and Quantitative Myasthenia Gravis ...

FREDERICK, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the "Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, ...

High rates of biologic naivety, limited switching, and ongoing unmet needs across the gMG landscape create opportunity for brand differentiation.< ...

Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today reported its business highlights ...

The MG-ADL scale assesses the impact of gMG on daily functions of ... At baseline, the median MG-ADL and Quantitative Myasthenia Gravis (QMG) total scores were 9 and 15, respectively; 88% of patients ...

Billionaire undergoes total plasma exchange, replacing his plasma with albumin and IVIG to reverse aging, enhance cognitive ...